Actively Recruiting
Pilot Study Evaluating Safety and Imaging Quality of MB-102 Dye Compared to Fluorescein Sodium in Adult Eye Angiography
Led by MediBeacon · Updated on 2026-02-04
10
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and image quality of a new dye called MB-102 compared to the standard dye fluorescein sodium. This study involves both healthy adults and those with retinal diseases such as retinopathy, retinal vein occlusion, diabetic retinopathy, and macular degeneration. The purpose is to see if MB-102 is feasible and safe for use in fluorescent angiography to help diagnose and monitor these eye conditions. Participants will receive two intravenous dye injections during the study. First, they will get the control dye fluorescein sodium, followed by eye imaging using a Zeiss fundus camera and, for some, other approved ocular angiography systems. At least three days later, they will receive a single dose of MB-102, followed by similar imaging procedures. This single-dose design allows comparison of the two dyes in the same participants. During the study, participants will have eye photographs taken to assess image quality and usefulness for disease evaluation. They will return for follow-up visits including physical exams, lab tests, and monitoring for any side effects or adverse events. The main outcome measured is whether MB-102 imaging is feasible compared to fluorescein sodium, with safety monitored up to 24 days after enrollment. Participation lasts up to about two weeks after dye administration.
CONDITIONS
Brief Title
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
Research Team
R
Richard B Dorshow, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here